NRX Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: NRXPW · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $25.0 million, $2.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
NRX Pharma 8-K: Director/officer changes and compensation details filed Jan 22.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on January 22, 2025, reporting events as of January 15, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also covers other events and financial statements/exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation arrangements can indicate internal shifts that may impact future performance.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former Company Name
FAQ
What specific officer or director positions were affected by the events reported in the 8-K?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers'.
When were the earliest events reported in this 8-K dated?
The earliest event reported in this 8-K was dated January 15, 2025.
What is the SEC file number for NRX Pharmaceuticals, Inc.?
The SEC file number for NRX Pharmaceuticals, Inc. is 001-38302.
What is the primary business SIC code for NRX Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for NRX Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.
Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2025-01-22 16:32:42
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
- $25.0 million — y the Investor intends to purchase: (i) $25.0 million in shares of HOPE's Series A Preferred
- $2.0 million — Common Stock ") for a purchase price of $2.0 million. Mr. Taylor, will serve until the Comp
Filing Documents
- nrxp20250122_8k.htm (8-K) — 33KB
- ex_768584.htm (EX-99.1) — 9KB
- 0001437749-25-001569.txt ( ) — 196KB
- nrxp-20250115.xsd (EX-101.SCH) — 4KB
- nrxp-20250115_def.xml (EX-101.DEF) — 14KB
- nrxp-20250115_lab.xml (EX-101.LAB) — 18KB
- nrxp-20250115_pre.xml (EX-101.PRE) — 14KB
- nrxp20250122_8k_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 15, 2025, NRx Pharmaceuticals, Inc. (the " Company ") appointed Mike Taylor as a Class I member of the Board of Directors of the Company (" Board "). Mike Taylor, 50, is a 25-year veteran in the global credit business, focused on special situations and capital formation. Mr. Taylor currently serves as a consultant to Hope Therapeutics, Inc., a wholly-owned subsidiary of the Company. Mr. Taylor previously served as a Partner of the Adi Dassler International Family office wealth advisory firm from August 2016 to February 14, 2023; as Managing Director at Oppenheimer & Co. Inc. from June 2011 to August 2016, a New York-based full-service brokerage and investment bank, focusing on complex debt structuring and transactions and multijurisdictional capital formation, and as Managing Director of Institutional Fixed Income Trading and Alternative Investments at Stone & Youngberg LLC, a private investment firm, from July 2004 to June 2011. Mr. Taylor began his career with Morgan Stanley as a Bond Trader. Mr. Taylor holds a Bachelor of Science degree in Economics & International Relations from the London School of Economics. Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025. Mr. Taylor was designated to serve on the Board by JGS Holdings LLC, a Wyoming limited liability company (the " Investor "), in connection with the execution of that certain term sheet entered into on January 5, 2025 (the " Term Sheet ") by and between the Company, HOPE Therapeutics, Inc., a wholly-owned subsidiary of the Company (" HOPE "), and the Investor, whereby the Investor intends to purchase: (i) $25.0 million in shares of HOPE's Series A Preferred Stock convertible into one-third of all fully diluted outstanding equity of HOPE; and (ii) 730,000
01
Item 8.01 Other Events. January 21, 2025, the Company issued a press release announcing that the Company received a written notice from The Nasdaq Stock Market (" Nasdaq ") that the Company has regained compliance with the minimum market value of listed securities requirement under NASDAQ Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. A copy of the Press Release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1* Press Release, dated January 21, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL). * Furnished herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: January 22, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer